Important information

  • Of the 17 pediatric patients 2 months to <2 years of age in 3 open-label studies, 7 patients (41%) reported a total of 11 hyperammonemic crises.1
  • Of the 26 pediatric patients 6 to 17 years of age in two 12-month studies of RAVICTI, 5 patients (19%) reported a total of 5 hyperammonemic crises.1
  • Of 51 adult patients in a 12-month study of RAVICTI, 7 patients (14%) reported a total of 10 hyperammonemic crises.1

aSix uncontrolled, open-label studies were conducted to assess monthly ammonia control and hyperammonemic crises in patients with urea cycle disorders (UCDs): 17 pediatric patients 2 months to <2 years of age, with 6 patients completing 12 months of treatment; 26 pediatric patients 6 to 17 years of age over a 12-month period; and 51 adults over a 12-month period.1

Get information about RAVICTI dosing

Calculate the appropriate starting dose for treatment-naïve patients, quickly convert the dosage from NaPBA to RAVICTI, and optimize the RAVICTI dosage.

Visit Dosage Guide

Stay informed about RAVICTI® (glycerol phenylbutyrate) Oral Liquid

Thank you

Sign up to get the latest information that can help guide your patient management decisions. Fields marked with an asterisk are required.

IMPORTANT: The information you provide in this form will be used in accordance with the Horizon Pharma Privacy Policy. I understand that the information I am providing may be used by Horizon Pharma plc to provide me with health and product information and related services concerning health conditions. By submitting this form, I consent to these uses and understand that I must be 18 years or older to receive these mailings.

References:  1. RAVICTI [package insert]. Lake Forest, IL: Horizon Pharma USA, Inc.; 2019.  2. Mosteller RD. N Engl J Med. 1987;317(17):1098. doi:10.1056/nejm198710223171717.